CytoDyn Inc. (OTCQB: CYDY) is entering a Phase 3 clinical trial with its leading product candidate, PRO 140, and the Washington-based biotech is showing a lot of progress nearing major milestones. PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that work by blocking the entry of the human immunodeficiency virus (HIV) […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.